冠心病PCI手术患者抑酸药物的选用分析  

Analysis of acid-suppressive drug choice after PCI in patients with coronary heart diseases

作　　者：杜瑜[1] 王淼[2] 潘金水[3] 

机构地区：[1]厦门大学附属中山医院药学部,厦门361004 [2]厦门大学附属中山医院呼吸内科,厦门361004 [3]厦门大学附属中山医院消化内科,厦门361004

出　　处：《中国新药杂志》2013年第8期975-978,982,共5页Chinese Journal of New Drugs

摘　　要：目的:通过对中山医院(以下简称我院)冠心病经皮冠状动脉支架手术(percutaneous coronary interventions,PCI)患者应用抑酸药物的情况进行分析,为临床合理用药提供参考。方法:抽查我院179例进行了PCI手术患者的病例,统计其抑酸药物的使用品种、给药方案、药物更换及合并用药等。结果:调查病例中有87.71%的患者应用了抑酸药物预防上消化道出血(upper gasteointestinal,UGI),平均使用天数为(10.39±8.59)d;主要选择的抑酸药物为雷贝拉唑、泮托拉唑和法莫替丁;联合使用药物最多的是铝碳酸镁。结论:对于接受双联抗血小板治疗的PCI手术患者,目前尚缺乏指南来指导其科学地预防UGI,因此需要更进一步的临床研究来保障其用药安全,促进抑酸药物在该类患者中的合理应用。Objective： To analyze the acid-suppressive drug use after percutaneous coronary interventions （PCI） in patients with coronary heart diseases in Zhongshan Hospital, so as to provide references for their rational use. Methods： Totally 179 medical records of the patients having received PCI were reviewed. Their varieties, do- sing regimens, drug replacement and concomitant medications of acid-suppressive drugs were surveyed. Results： Acid-suppressive drugs were used in 87.71% patients during the treatment, and the average use duration of each patient was （10.39 ±8.59） d. Rabeprazole, pantoprazole and famotidine were the most used acid-suppressive drugs. Hydrotatcite was the most used drug in combination with other drugs. Conclusion： There is no guidelines for the scientific prevention of UGI in patients receiving double antiplatelet therapy after PCI, therefore, the further clinical research is necessary to ensure the safe and rational use of acid-suppressive drugs.

关 键 词：冠心病 经皮冠脉支架植入术 抑酸药物 质子泵抑制剂 上消化道出血 合理用药 

分 类 号：R972[医药卫生—药品]